Anteris Technologies GlobalASX:AVR +10.05%50 PB Ratio is 3.68 as of Jun. 25, 2026, which is 6% below its 10-year median of 3.93. GuruFocus rates ASX:AVR with a GF Score™ of 50/100. The stock has 7 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 70.65% on this metric.
The historical rank and industry rank for Anteris Technologies Global's PB Ratio or its related term are showing as below:
ASX:AVR'
s PB Ratio Range Over the Past 10 Years
Min: 1.92 Med: 3.93 Max: 54.27
Current: 3.95
During the past 13 years, Anteris Technologies Global's highest PB Ratio was 54.27. The lowest was 1.92. And the median was 3.93.
ASX:AVR's PB Ratio is ranked worse than 70.65% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs ASX:AVR: 3.95
During the past 12 months, Anteris Technologies Global's average Book Value Per Share Growth Rate was 138.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Anteris Technologies Global was 54.40% per year. The lowest was -65.00% per year. And the median was -23.95% per year.
Back to Basics: PB Ratio
Anteris Technologies Global (ASX:AVR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Anteris Technologies Global PB Ratio Related Terms
Anteris Technologies Global PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Anteris Technologies Global's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's PB Ratio distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Anteris Technologies Global (ASX:AVR) has a PB Ratio of 3.68 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anteris Technologies Global and its competitors. This is near median its historical median of 3.93. Over the past decade, Anteris Technologies Global's PB Ratio has ranged from 1.92 to 54.27. According to the industry distribution chart, Anteris Technologies Global ranks #556 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 70.6%.
Is Anteris Technologies Global's PB Ratio too high?
Anteris Technologies Global's current PB Ratio of 3.68 is near median its 10-year median of 3.93. Over the past 10 years, this metric has ranged from a low of 1.92 to a high of 54.27. The Medical Devices & Instruments industry median PB Ratio is 2.04. Anteris Technologies Global's value of 3.68 is 80.4% above this industry median. Based on the distribution chart, Anteris Technologies Global ranks #556 out of 787 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Anteris Technologies Global has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's PB Ratio compare to INMD and QDEL?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #556 out of 787 companies for PB Ratio. This places Anteris Technologies Global in the lower half of its industry. The industry median PB Ratio is 2.04. Anteris Technologies Global's value of 3.68 is 80.4% above this benchmark. Historically, Anteris Technologies Global's own PB Ratio has ranged from 1.92 to 54.27 over the past decade. While the company's 10-year median is 3.93 vs. the industry median of 2.04, Anteris Technologies Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anteris Technologies Global's current PB Ratio of 3.68 is 80.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current PB Ratio is 3.68, which is near median its own 10-year median of 3.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current PB Ratio of 3.68. The current PB Ratio is 3.68, which is near median its 10-year median of 3.93 and 80.4% above the Medical Devices & Instruments industry median of 2.04. Anteris Technologies Global's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current PB Ratio is 3.68 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score
Get the complete analysis for ASX:AVR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
